Also known as: Arcturus Therapeutics
Arcturus Therapeutics is a messenger RNA medicines company focused on liver and respiratory rare disease therapeutics. Its platform includes LUNAR lipid delivery, STARR self-amplifying mRNA technology, and mRNA drug substance and product manufacturing capabilities.
April 2 biotech value screen names Bicycle Therapeutics, Novavax, and PTC Therapeutics. Novavax earned an A Value Grade; February screens included Arcturus, Emergent, Puma, Rigel, and Sutro.
Arcturus Therapeutics completed three 28-day inhaled mRNA cohorts for cystic fibrosis that were well-tolerated and showed early biological signals. The company is preparing a 12-week Phase 2 study with tightened eligibility criteria and expanded enrollment into Europe and the Middle East.
Arcturus Therapeutics will release fourth quarter and fiscal year 2025 financial results after market close on March 3, 2026, followed by a conference call at 4:30 p.m. Eastern Time.
The mRNA therapy market is forecast to grow from USD 13.6 billion in 2025 to USD 70.0 billion by 2035 at a 17.8% CAGR, driven by expanding applications beyond vaccines into oncology, rare diseases, and infectious disease treatments including genital herpes.
